CANbridge Pharmaceuticals has exercised its option to secure the exclusive global rights to develop, manufacture and commercialise a novel gene therapy to treat spinal muscular atrophy (SMA) from UMass Chan Medical School. Animal data presented in 2022 showed that the gene therapy outperformed the benchmark therapy along multiple key endpoints in a mouse model of […]
